|
 |
|
|
|
|
|
Speakers The speaker panel for the Washington Vaccine Forum 2009 is now almost complete. Amongst those high profile figures who have already confirmed their participation are: Dr Mikael Dolsten, President, Research & Development, Wyeth Pharmaceuticals, Senior Vice President, Wyeth Corporation Dr Michel De Wilde, Senior Vice President, Research & Development, sanofi pasteur Dr Robin Robinson, Director, Biomedical Advanced Research & Development Authority (BARDA), Office of the Assistant Secretary for Preparedness & Response (ASPR), US Department of Health & Human Services Dr Allan P. Jarvis, Senior Vice President, Corporate Development, sanofi pasteur Dr Gary J. Nabel, Director, Vaccine Research Center, National Institute of Allergy & Infectious Diseases (NIAID), NIH Anne Schuchat, MD, RADM, US Public Health Service, Assistant Surgeon General, Director, National Center for Immunization & Respiratory Diseases, Centers for Disease Control & Prevention Dr Robert Kadlec, Special Assistant to the President for Homeland Security & Senior Director for Biological Defense Policy Dr Norman W. Baylor, Director, Office of Vaccines Research & Review (OVRR), CBER, US Food & Drug Administration Peter Ehrenheim, President & CEO, GE Healthcare Life Sciences Drs Ben Machielse, Executive Vice President, Operations, MedImmune, Inc Hartmut J. Ehrlich, MD, Vice President, Global R&D, Baxter BioScience Carl W. Dieffenbach, PhD, Director of the Division of AIDS (DAIDS), National Institute for Allergies & Infectious Diseases (NIAID), NIH Dr John W. Shiver, Vice President, Worldwide Basic Research Franchise Head, Vaccines, Merck Research Laboratories Dr Karen J. Huebscher, Global Head of Business Development & Licensing, Novartis Vaccines and Diagnostics Dr Keith Gottesdiener, Vice President & Head of Clinical Vaccines & Infectious Diseases, Merck Research Laboratories Dr Jerald C. Sadoff, President & CEO, Aeras Global TB Vaccine Foundation Dr Douglas J. Pon, Assistant Vice President, Vaccine Licensing, Global Business Development, Wyeth Pharmaceuticals Heather L. Davis, PhD, Executive Director, Pfizer Global R&D, Vaccines Research; Site Head, Ottawa Laboratories Christian Mandl MD, PhD, Vice President & Global Head of Virology, Head of Research, US, Novartis Vaccines and Diagnostics, Inc Bill Helming, Vice President, Biodefense & Public Health Practice, PRTM Management Consultants LLC Elisabeth Lindner, CEO & President, Diamyd Medical AB Ian Sellick, Marketing Director, Pall Life Sciences Vijay B. Samant, President & CEO, Vical, Inc Dr James Jackson, Chief Scientific Officer, Emergent Biosolutions Thomas E. Shrader, PhD, CFA, Managing Director, Healthcare Research, Rodman & Renshaw, LLC Una S. Ryan, OBE, PhD, President & CEO, Waltham Technologies, Inc Dr Alan Carr, Life Sciences Analyst, Needham & Company, LLC Dr Gregory M. Glenn, Chief Scientific Officer, Intercell USA, Inc Dr Michael G. Kurilla, Director, Office of BioDefense Research Affairs, Associate Director for BioDefense Product Development, DMID, NIAID, NIH, DHHS Robert V. House, PhD, President, DynPort Vaccine Company, LLC, Frederick, MD Dr Jeffrey Schlom, Chief, Laboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Institute Dr Darrell R. Galloway, Director, Joint Science & Technology Office, Chemical & Biological Defense Directorate, Defense Threat Reduction Agency, US Department of Defense Dr Shou-Bai Chao, Vice President, Vaccines Manufacturing, MedImmune, Inc Lada Rasochova, PhD, MBA, Manager, Vaccine Technologies, Pf_nex Dr Clement Lewin, Head, Strategic Immunization Planning, Novartis Vaccines and Diagnostics Alan S. Taggart, Vice President, Government Project Management, MedImmune, Inc Dr Mark Feinberg, Vice President, Policy, Public Health & Medical Affairs, Merck Vaccine Division Dr Mark A. Tomai, Head of Vaccine Business Development, 3M Drug Delivery Systems Dr Michael V. Callahan, Program Manager, Rapid Vaccine Assessment (RVA), Defense Advanced Research Projects Agency (DARPA) Dr Tonya Villafana, Director, Portfolio Management, PATH Malaria Vaccine Initiative (MVI) Dr Suresh Jadhav, Executive Director, Serum Institute of India Ltd Dr Thomas P. Monath, Partner, Kleiner Perkins Caufield & Byers Dr John Boslego, Director, Vaccine Development Global Program, PATH Dr David L. Urdal, CSO, Dendreon Corporation Dr Stephen Lockhart, Senior Vice President, Product Development, Emergent Biosolutions Raafat E. F. Fahim, PhD, President & CEO, Nabi Biopharmaceuticals Dr Phillip Gomez, Principal, PRTM Dr Rahul Singhvi, President & CEO, Novavax, Inc Drew Hannaman, Vice President, R&D, Ichor Medical Systems, Inc Dr Christoph S. Klade, Vice President, Technology Development & Clinical Immunology, Intercell AG Dr Luc Hessel, Executive Director, Policy Affairs, Europe, sanofi pasteur MSD Beth Wensley, Vice President, Project Management, MedImmune, Inc Drs Manon Cox, MBA, Chief Operating Officer, Protein Sciences Corporation Dr Christopher D. Earl, President & CEO, BIO Ventures for Global Health Dr Ian Henderson, Chief Scientific Officer, DynPort Vaccine Company, LLC, Frederick, MD Louis Z. Cooper, MD, Professor Emeritus of Pediatrics, Columbia University, Former President, American Academy of Pediatrics & Trustee, Sabin Vaccine Institute Professor Angus Dalgleish, Professor of Oncology, St George's, University of London & Research Director, Onyvax Limited Dr Jill Gilmour, Senior Director, Clinical Immunology, International AIDS Vaccine Initiative Dr Vidadi Yusibov, Executive Director, Fraunhofer Center for Molecular Biotechnology William M. Egan, PhD, Vice President, PharmaNet Consulting Dr Xinbin Gu, President, TenGen Biomedical Dr Ronald W. Ellis, Senior Vice President & Chief Technical Officer, NasVax Ltd, Israel Dr Charles Richardson, Executive Vice President, R&D, LigoCyte Pharmaceuticals, Inc Narender Dev Mantena, Senior Vice President, Strategic Business Development, Biological E. Limited Shankar Musunuri, PhD, MBA, Senior Director & Strategic Product Leader, Wyeth Biotech Helen McShane, FRCP, PhD, Wellcome Senior Clinical Fellow & Honorary Consultant Physician, The Jenner Institute, Oxford University Michael L. Dekleva, PhD, Senior Director, World Wide Regulatory Affairs, Vaccines/Biologics, Merck & Co, Inc Carla Botting, Director, Quality Management & Commercial Affairs, PATH Malaria Vaccine Initiative (MVI) Professor Dr Achim Schneeberger, Head of Clinical Development, AFFiRiS GmbH Dr Charles G. Drake, Assistant Professor of Medical Oncology, Immunology & Urology, Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University Dr David Kirke, Senior Consultant, ERA Consulting Group Wendy Taylor, Vice President of Strategy & Operations, BIO Ventures for Global Health Peter Zerhouni, Director of Business Development, Diamyd Medical AB Professor Steven J. Czinn, Chair, Department of Pediatrics, University of Maryland School of Medicine Dr Janine T. Bryan, Senior Research Fellow & HPV Lead, Department of Vaccines Basic Research, Merck Research Laboratories Visit this page again soon to find out who else you will be able to hear from – and meet – in Washington this coming January.
|
|
